2017, Number 3
<< Back Next >>
Acta Pediatr Mex 2017; 38 (3)
Mutation m. › C in the MT- TL1 gene in Mitochondrial Encephalopathy, Lactic Acidosis and Stroke Like Episodes (MELAS) in pediatric age. Case report
García-Beristain JC, Barragán-Pérez EJ
Language: Spanish
References: 19
Page: 165-174
PDF size: 839.46 Kb.
ABSTRACT
Introduction: Mitochondrial Encephalopathy, Lactic Acidosis and
Stroke-like episodes (MELAS) is a rare metabolic disease that usually presents with seizures and
stroke-like episodes in young people. It been determined that 7 to 15% of patients with MELAS have transitions T to C at nucleotide position 3271 (
T3271C). Most patients reported with this association are of Japanese origin. Altered mental status and schizophrenia can sometimes precede or accompany
stroke-like episodes in MELAS; they can be found even in families affected by the same mutation
T3271C. Children with MELAS have a wide range of clinical presentations, which are predominant Stroke-like episodes.
Objetive: To describe the clinical findings related to
m.3271 ›
C mutation of the
MT- TL1 gene in MELAS syndrome in this pediatric case.
Clinic case: A case of an 11 years old female who presents clinical evidence of Cerebral Vascular Accident (CVA) with visual manifestation followed by hemodynamic deterioration, severe shock whit hyperlactatemia and acid-base imbalance. It was determined that there was mutation
m.3271T›
C heteroplasmy in the
MT-TL1 gene compatible with MELAS.
Conclusions: We believe that patients with stroke, abnormal acid-base and severe hiperlactatemia could lead to hemodynamic instability or shock, in direct relation with this mutation. Therefore these patients must be immediately studied to make the suspected diagnosis. The study must include molecular confirmation before the condition become aggressive and progressive.
REFERENCES
Goodfellow J, Dani K, Stewart W, Santosh C, McLean J, Mulhern S et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: an important cause of stroke in young people. Postgraduate Medical Journal. 2012;88(1040):326-334.
Stenqvist L, Paetau A, Valanne L, Suomalainen A, Pihko H. A Juvenile Case of MELAS with T3271C Mitochondrial DNA Mutation. Pediatric Research. 2005;58(2):258-262.
Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T et al. MELAS: A nationwide prospective cohort study of 96 patients in Japan. Biochimica et Biophysica Acta (BBA) - General Subjects. 2012;1820(5):619-624.
Mitani T, Aida N, Tomiyasu M, Wada T, Osaka H. Transient ischemic attack-like episodes without stroke-like lesions in MELAS. Pediatric Radiology. 2013;43(10):1400-1403.
Brisca G, Fiorillo C, Nesti C, Trucco F, Derchi M, Andaloro A et al. Early onset cardiomyopathy associated with the mitochondrial tRNALeu(UUR) 3271T>C MELAS mutation. Biochemical and Biophysical Research. Communications. 2015;458(3):601-604.
Yu N, Zhang Y, Zhang K, Xie Y, Lin X, Di Q. MELAS and Kearns–Sayre overlap syndrome due to the mtDNA m. A3243G mutation and large-scale mtDNA deletions. e Neurological Sci. 2016;4:15-18.
Lorenzoni P, Werneck L, Kay C, Silvado C, Scola R. When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? Arq Neuro-Psiquiatr. 2015;73(11):959-967.
Xie S. MR OEF Imaging in MELAS. Methods in Enzymology. 2014;:433-44.
Kitamura M, Yatsuga S, Abe T, Povalko N, Saiki R, Ushijima K et al. l- Arginine intervention at hyper-acute phase protects the prolonged MRI abnormality in MELAS. Journal of Neurology. 2016;263(8):1666-1668.
Fryer R, Bain J, De Vivo D. Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options. Pediatric Neurology. 2016;56:59-61.
Li R, Xiao H, Lyu J, J.J. Wang D, Ma L, Lou X. Differential diagnosis of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) and ischemic stroke using 3D pseudocontinuous arterial spin labeling. J Magn Reson Imaging. 2016. doi: 10.1002/jmri.25354
El-Hattab A, Adesina A, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular Genetics and Metabolism. 2015;116(1-2):4-12.
Glover E, Martin J, Maher A, Thornhill R, Moran G, Tarnopolsky M. A. randomized trial of coenzyme Q10in mitochondrial disorders. Muscle & Nerve. 2010;42(5):739-748.
Lam C, Lau C, Williams J, Chan Y, Wong L. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. European Journal of Pediatrics. 1997;156(7):562-564.
Finsterer JZarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opinion on Drug Metabolism & Toxicology. 2011;8(1):71-79.
Morin C, Dubé J, Robinson B, Lacroix J, Michaud J, De Braekeleer M et al. Stroke‐like episodes in autosomal recessive cytochrome oxidase deficiency. Annals of Neurology. 1999;45(3):389-392.
Vallée L, Fontaine M, Nuyts J, Ricart G, Krivosic I, Divry P et al. Stroke, hemiparesis and deficient mitochondrial β-oxidation. European Journal of Pediatrics. 1994;153(8):598-603.
DiMauro S. Mitochondrial encephalomyopathies: problems in pathogenesis. Electroencephalography and Clinical Neurophysiology. 1997;103(1):24-25.
Filosto M, Tomelleri G, Tonin P, Scarpelli M, Vattemi G, Rizzuto N, Padovani A, Simonati A. Neuropathology of mitochondrial diseases. Biosci Rep. 2007;27:23–30